From Investing.com: 2024-05-18 17:06:00

Longeveron Inc. (LGVN) reported positive first-quarter financial results for 2024, with a focus on their lead compound Lomecel-B showing promising results in Alzheimer’s and HLHS treatment studies. The company has seen an increase in revenues and a decrease in net loss, securing funding for operations into Q4 2024.

In addition to their financial updates, Longeveron has discontinued their Frailty clinical trial in Japan to prioritize HLHS development. They plan to finalize Phase 2 study enrollment for HLHS by year-end and present positive data from the Phase 2a Alzheimer’s trial at the Alzheimer’s Association International Conference in 2024. Longeveron is confident in the therapeutic potential of Lomecel-B and is actively engaging with the FDA on future clinical and regulatory strategies. With a strengthened balance sheet, the company is poised for advancements in regenerative medicine.

InvestingPro insights suggest that while Longeveron faces challenges in market conditions and stock performance, the company’s focus on advancing key therapeutic programs like Lomecel-B is crucial for potential growth. With a strong commitment to engaging regulatory authorities and optimizing clinical trial designs, Longeveron aims to overcome challenges in the regenerative medicine sector. Despite the volatility in their stock price, Longeveron’s strategic approach and positive trial results indicate promising prospects for the future. Visit https://www.investing.com/pro/LGVN for in-depth analysis and additional insights.



Read more at Investing.com: Longeveron reports Q1 2024 results, optimistic on Lomecel-B By Investing.com